Nifty
:
22147.90
Sensex
:
72943.68
-124.60 (-0.56%)
-456.10 (-0.62%)
Nifty
Sensex
:
:
22147.90
72943.68
-124.60 (-0.56%)
-456.10 (-0.62%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
68/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
944.85
16-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  932.00
  •  971.50
  •  926.20
  •  935.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2235559
  •  21280.12
  •  1031.70
  •  484.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 95,104.21
  • 31.98
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 94,347.11
  • 0.63%
  • 5.05

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.98%
  • 0.61%
  • 5.28%
  • FII
  • DII
  • Others
  • 5.72%
  • 12.53%
  • 0.88%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.09
  • 5.54
  • 6.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.59
  • 3.70
  • 1.08

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.81
  • 0.75
  • -4.60

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.38
  • 23.39
  • 23.22

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.11
  • 3.22
  • 3.27

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.59
  • 14.13
  • 14.68

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
4,505.20
4,257.10
5.83%
4,368.80
4,005.50
9.07%
5,139.60
3,964.30
29.65%
5,010.60
3,805.60
31.66%
Expenses
3,423.40
3,406.30
0.50%
3,304.90
3,319.40
-0.44%
3,634.30
3,239.70
12.18%
3,755.00
3,087.90
21.60%
EBITDA
1,081.80
850.80
27.15%
1,063.90
686.10
55.06%
1,505.30
724.60
107.74%
1,255.60
717.70
74.95%
EBIDTM
24.01%
19.99%
24.35%
17.13%
29.29%
18.28%
25.06%
18.86%
Other Income
58.30
143.70
-59.43%
136.20
173.60
-21.54%
36.00
174.30
-79.35%
37.80
79.10
-52.21%
Interest
19.80
32.80
-39.63%
8.70
35.10
-75.21%
18.10
34.30
-47.23%
27.70
38.50
-28.05%
Depreciation
194.80
181.60
7.27%
184.20
181.80
1.32%
179.80
180.70
-0.50%
178.60
185.40
-3.67%
PBT
925.50
780.10
18.64%
1,007.20
642.80
56.69%
1,329.20
681.00
95.18%
485.80
572.90
-15.20%
Tax
213.80
195.20
9.53%
226.40
137.00
65.26%
216.10
118.40
82.52%
137.20
109.20
25.64%
PAT
711.70
584.90
21.68%
780.80
505.80
54.37%
1,113.10
562.60
97.85%
348.60
463.70
-24.82%
PATM
15.80%
13.74%
17.87%
12.63%
21.66%
14.19%
6.96%
12.18%
EPS
7.80
6.16
26.62%
7.91
5.16
53.29%
10.74
5.06
112.25%
2.93
3.88
-24.48%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
19,024.20
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
Net Sales Growth
18.66%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
 
Cost Of Goods Sold
6,312.70
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
Gross Profit
12,711.50
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
GP Margin
66.82%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
Total Expenditure
14,117.60
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
Power & Fuel Cost
-
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
129.70
% Of Sales
-
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
Employee Cost
-
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
% Of Sales
-
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
Manufacturing Exp.
-
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
% Of Sales
-
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
General & Admin Exp.
-
737.70
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
302.70
% Of Sales
-
4.28%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
Selling & Distn. Exp.
-
1,557.20
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
% Of Sales
-
9.03%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
Miscellaneous Exp.
-
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
330.50
980.50
% Of Sales
-
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
EBITDA
4,906.60
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
EBITDA Margin
25.79%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
Other Income
268.30
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
85.90
Interest
74.30
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
Depreciation
737.40
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
201.20
PBT
3,747.70
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
Tax
793.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
106.00
Tax Rate
21.17%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
PAT
2,954.20
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
PAT before Minority Interest
2,843.10
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
Minority Interest
-111.10
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
PAT Margin
15.53%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
PAT Growth
39.55%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
 
EPS
29.36
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79
11.41
7.99

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
Share Capital
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
Non-Current Liabilities
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
Secured Loans
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
Unsecured Loans
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
Long Term Provisions
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
Current Liabilities
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
Trade Payables
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
Other Current Liabilities
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
Short Term Borrowings
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
Short Term Provisions
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
Total Liabilities
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
Net Block
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
Gross Block
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
Accumulated Depreciation
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
Non Current Assets
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
Capital Work in Progress
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
Non Current Investment
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
Long Term Loans & Adv.
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
Other Non Current Assets
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
Current Assets
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
Current Investments
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
Inventories
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
Sundry Debtors
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
Cash & Bank
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
Other Current Assets
985.70
229.90
523.90
441.60
1,080.50
1,048.40
348.50
358.90
311.50
323.50
Short Term Loans & Adv.
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
254.90
Net Current Assets
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
Total Assets
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
PBT
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
Adjustment
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
Changes in Working Capital
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
Cash after chg. in Working capital
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
Cash From Investing Activity
1,171.20
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
Net Fixed Assets
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
Net Investments
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
Others
1,601.80
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
Cash from Financing Activity
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
Net Cash Inflow / Outflow
-540.40
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
Opening Cash & Equivalents
1,106.90
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
Closing Cash & Equivalent
573.10
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
ROA
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
ROE
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
ROCE
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
Fixed Asset Turnover
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
1.63
Receivable days
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
51.71
Inventory Days
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
63.89
Payable days
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
49.83
Cash Conversion Cycle
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
65.78
Total Debt/Equity
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
Interest Cover
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29
8.98

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • USFDA completes inspection at Zydus Lifesciences’ SEZ Onco Injectable manufacturing plant
    28th Mar 2024, 10:38 AM

    The inspection closed with 4 observations

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Letermovir Tablets
    23rd Mar 2024, 16:26 PM

    Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus in people who have received a bone marrow transplant or kidney transplant

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Finasteride and Tadalafil Capsules
    18th Mar 2024, 11:08 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India

    Read More
  • Zydus gets USFDA’s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials
    14th Mar 2024, 12:48 PM

    The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Edaravone Injection
    14th Mar 2024, 12:23 PM

    The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara

    Read More
  • Zydus Lifesciences launches Olaparib
    13th Mar 2024, 17:13 PM

    The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach

    Read More
  • Zydus Lifesciences gets EIR report for API Ahmedabad facility
    11th Mar 2024, 10:11 AM

    This facility underwent an inspection from December 14 to 22, 2023 and has been classified as Voluntary Action Indicated

    Read More
  • Zydus Lifesciences gets post application action letter for cGMP, PAI at Ahmedabad facility
    7th Mar 2024, 12:30 PM

    This confirms that the inspected facility has been considered as ready to commercially manufacture and supply the Enzalutamide API

    Read More
  • Zydus Lifesciences gets WHO prequalification approval for Miltefosine formulation, API
    26th Feb 2024, 10:00 AM

    With this, Miltefosine will be added to WHO’s pre-qualification list which will enable larger access to the drug globally

    Read More
  • Zydus Lifesciences incorporates wholly owned subsidiary in UAE
    23rd Feb 2024, 09:58 AM

    The company has incorporated WOS on February 20, 2024

    Read More
  • Zydus Lifesciences gets final nod for Isosorbide Mononitrate Extended-Release Tablets
    16th Feb 2024, 16:09 PM

    Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg had annual sales of $47 million in the United States

    Read More
  • Zydus Lifesciences reports 27% rise in Q3 consolidated net profit
    9th Feb 2024, 17:07 PM

    Total consolidated income of the company increased by 5.76% at Rs 4542.90 crore for Q3FY24

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Dexamethasone Tablets
    9th Feb 2024, 15:39 PM

    The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh

    Read More
  • Zydus Lifesciences - Quarterly Results
    9th Feb 2024, 12:56 PM

    Read More
  • Zydus Lifesciences gets final nods for Dexamethasone Tablets
    8th Feb 2024, 16:13 PM

    The company has also received final approval to market Dexamethasone Tablets USP, 2 mg

    Read More
  • Zydus Lifesciences launches Relugolix
    30th Jan 2024, 10:41 AM

    The drug will be manufactured at the group’s manufacturing premises

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Gabapentin tablets
    25th Jan 2024, 15:27 PM

    The product will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences’ arm enters into licensing and supply agreement with Synthon BV
    19th Jan 2024, 09:05 AM

    Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets, and thereafter, for the manufacturing and supply of the product

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Pimavanserin Capsules, Pimavanserin Tablets
    18th Jan 2024, 09:10 AM

    Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.